

The Canadian Cervical Cancer Screening Trial of human papillomavirus (HPV) testing versus Pap cytology

Submission date 09/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 09/09/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 05/01/2010	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Eduardo L.F. Franco

Contact details
Division of Cancer Epidemiology
McGill University
546 Pine Avenue West
Montreal
Canada
H2W 1S6
+1 514 398 6032
eduardo.franco@mcgill.ca

Additional identifiers

Protocol serial number
MCT-54063

Study information

Scientific Title

Efficacy trial of human papillomavirus (HPV) versus Pap testing for screening cervical cancer precursors: a randomised controlled trial

Acronym

CCCaST

Study objectives

Objectives:

1. To compare human papillomavirus (HPV) testing with Pap cytology to detect prevalent and early incident asymptomatic cervical cancers and their high-grade precancerous lesions among women aged 30 - 69 years who present for their routine cervical cancer screening in Montreal and Newfoundland
2. To identify individual, social, and health care delivery variables that influence the performance of the Pap smear and of HPV testing and determine the costs of delivery of those two screening strategies in the two populations chosen for the study

As of 05/01/2010 this record was updated; all details can be found under the relevant section with the above update date. At this point, the target number of participants field was also updated; the initial target number of participants at time of registration was 12,000. However, 14,953 women were assessed for eligibility and invited to participate and 10,154 were randomised into the trial.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Institutional Review Board of McGill University on the 26th April 2005. Ethics approval has been extended to several additional clinics and institutions involved in the study.

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Screening

Health condition(s) or problem(s) studied

High-grade cervical intra-epithelial neoplasia

Interventions

Pap testing compared to HPV testing.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Biopsy-proven cervical intraepithelial neoplasia (CIN 2, 3) (high grade intraepithelial lesion [HSIL]) or cancer, ascertained at 6, 12, and 18 months

Key secondary outcome(s)

Biopsy-proven CIN 1 (low grade intraepithelial lesion [LSIL]) at 18 months.

Completion date

31/07/2007

Eligibility

Key inclusion criteria

Current inclusion criteria as of 05/01/2010:

1. Women aged 30 to 69 years
2. Sought screening tests for cervical cancer in any of 30 family practice or gynaecology clinics in Montreal and St. John's, Canada

Initial inclusion criteria at time of registration:

1. Women aged between 30 and 69 years
2. Currently attending a colposcopy clinic for evaluation, treatment or follow up of a cervical lesion

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

Current exclusion criteria as of 05/01/2010:

1. Currently being followed up for a cervical lesion
2. Lacked a cervix
3. Pregnant
4. Had a history of cervical cancer
5. Had undergone Pap testing in the previous year
6. Unable to provide consent were excluded (note that this is related also to the ability to understand French or English)

Initial exclusion criteria at time of registration:

1. Without a cervix
2. Pregnant
3. History of cervical cancer
4. Known human immunodeficiency virus (HIV) infection

- 5. Mentally incompetent
- 6. Unable to understand French or English
- 7. Refuse to provide an informed consent

Date of first enrolment

26/09/2002

Date of final enrolment

31/07/2007

Locations

Countries of recruitment

Canada

Study participating centre**Division of Cancer Epidemiology**

Montreal

Canada

H2W 1S6

Sponsor information

Organisation

McGill University (Canada) - Research Grants Office

ROR

<https://ror.org/01pxwe438>

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - <http://www.cihr-irsc.gc.ca> (ref: MCT-54063)

Funder Name

Merck-Frosst (Canada) - unrestricted educational grant

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	18/10/2007		Yes	No
Protocol article	protocol	01/08/2006		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes